

**IN THE CLAIMS**

Please amend the claims as follows:

1. (PREVIOUSLY PRESENTED) A composition comprising a TNP-470 conjugated to a polymer, wherein the polymer is water soluble and has a molecular weight in the range of 100Da to 800 kDa.
2. (PREVIOUSLY PRESENTED) The composition of claim 1, wherein the polymer has a molecular weight no greater than 60 kDa.
3. (PREVIOUSLY PRESENTED) The composition of claim 1, wherein the polymer has a molecular weight in the range of 15 to 40 kDa.
4. (PREVIOUSLY PRESENTED) The composition of claim 1, wherein the polymer is a hydroxypropyl(meth)acrylamide-methacrylic acid copolymer.
5. (PREVIOUSLY PRESENTED) The composition of claim 1, further comprising a peptide linker between the TNP-470 and the polymer.
6. (PREVIOUSLY PRESENTED) The composition of claim 1, further comprising a targeting ligand.



10. (PREVIOUSLY PRESENTED) A method for decreasing neurotoxicity of TNP-470, comprising conjugating the TNP-470 to a polymer, wherein the polymer is water soluble and has a molecular weight in the range of 100 Da to 800 kDa.
11. (CURRENTLY AMENDMED) The ~~composition~~ method of claim ± 10, wherein the polymer has a molecular weight no greater than 60 kDa.
12. (CURRENTLY AMENDMED) The ~~composition~~ method of claim ± 10, wherein the polymer has a molecular weight in the range of 15 to 40 kDa.
13. (PREVIOUSLY PRESENTED) The method of claim 10, wherein the polymer is a hydroxypropyl(meth)acrylamide-methacrylic acid copolymer.
14. (PREVIOUSLY PRESENTED) The method of claim 10, further comprising a peptide linker between the antiangiogenic agent and the polymer.



